BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Research Pipeline · 14 Sep 2026
BPC-157: The Gastric Pentadecapeptide With Three Decades of Animal Data, a 2026 MDPI Formulation Review, and No Completed Phase II Trial
BPC-157 has accumulated more than a hundred preclinical publications over thirty years, yet as of mid-2026 it has no completed Phase II human trial on record, no approved formulation, and no validated dosing regimen. A May 2026 review in Pharmaceutics catalogues the biopharmaceutical barriers that have stalled clinical translation, while the MHRA's April 2026 investigation into peptide clinics making health claims about the compound underscores the regulatory distance between animal evidence…
Read briefing →
Research Pipeline
MOTS-c: The Mitochondria-Encoded Peptide With a 7-5 PCAC Vote, a Metabolic Evidence Base Built Largely in Rodents, and No Human Drug-Product Data on Record
MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA and studied for metabolic regulation, insulin sensitivity, obesity, and bone health. On 23 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 7-5, with two abstentions, to recommend it for the 503A Bulks List — a narrow margin that reflects both scientific interest and the thinness of the human evidence base.
13 Sep 2026
Research Pipeline
KPV: The Alpha-MSH Tripeptide With a Favourable PCAC Vote, an Intracellular NF-κB Mechanism, and No Completed Human Trial
KPV is a synthetic tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone that has attracted research interest for its anti-inflammatory properties in gut and skin models. Following its removal from the FDA's Category 2 list in April 2026 and a favourable advisory committee vote in July, its regulatory trajectory is moving — but its human evidence base remains effectively absent.
12 Sep 2026
Reputational Risks
FDA's September 2026 Peptide Vendor Sweep: Five Warning Letters, One Clear Doctrine on "Research Use Only" Claims
On 1 September 2026, the FDA posted five coordinated warning letters to online peptide vendors — Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC — each cited for marketing unapproved drugs under the guise of research-use-only labelling. The sweep reinforces a doctrine the agency has applied with increasing consistency: website context, bundled reconstitution guides, and dosing calculators can establish human-use intent…
11 Sep 2026
Regulatory & Policy
After the PCAC Vote: The Three Legal Steps Between a Committee Recommendation and Lawful Peptide Compounding
The FDA's Pharmacy Compounding Advisory Committee recommended six peptides — including BPC-157, KPV, TB-500, and MOTS-c — for the 503A Bulks List in July 2026. But a committee recommendation is not compounding authorisation. This briefing maps the three distinct legal events that must follow before a pharmacy may lawfully compound these substances, and what the timeline means for UK research procurement.
10 Sep 2026
Research Pipeline
Semax: The ACTH-Derived Heptapeptide With an 8-5 PCAC Vote, Russian Clinical Approval, and a Research-Use-Only Status in the UK
Semax, a synthetic heptapeptide derived from the ACTH(4–10) fragment, received a favourable 8-5 vote from the FDA's Pharmacy Compounding Advisory Committee on 24 July 2026 — overriding its own agency scientists — for proposed neurological indications. It remains unapproved in the US and UK, where it may be supplied only for research use, but a decades-long evidence base and Russian clinical approval make it one of the more scientifically documented compounds now in the 503A rulemaking queue.
09 Sep 2026
Research Pipeline
Thymosin Alpha-1: The 28-Amino-Acid Immune Modulator With Approval in 35 Countries, an Unsettled US Compounding Status, and Active 2026 Clinical Trials
Thymosin alpha-1 (Tα1, thymalfasin) occupies an unusual position in the peptide landscape: it is approved as Zadaxin in more than 35 countries for chronic hepatitis B, yet holds no FDA approval and has navigated a turbulent US compounding regulatory path since 2023. With a 2026 NIH-registered trial now under way and a PCAC determination still pending, procurement teams need a clear account of where this compound stands.
08 Sep 2026
Regulatory & Policy
Orforglipron (Foundayo) Receives MHRA Authorisation: What the UK's First Oral Small-Molecule GLP-1 Approval Means for Research and Procurement
The MHRA authorised orforglipron (Foundayo) on 10 August 2026, making the UK the first country in Europe to approve the once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes. A NICE appraisal is expected by 18 November 2026, meaning NHS access remains a 2027 prospect at the earliest. Simultaneously, the FDA is moving to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, closing the last large-scale compounding pathway in the…
07 Sep 2026
Research Pipeline
TB-500: The Thymosin Beta-4 Fragment With an 8-6 PCAC Vote, a Scoping Review Confirming the Evidence Gap, and a Rulemaking Clock Now Ticking
TB-500, a synthetic fragment of thymosin beta-4, received a favourable 8-6 advisory vote at the FDA's July 2026 PCAC meeting, placing it on the path toward potential 503A compounding inclusion. A peer-reviewed scoping review published the same month confirms that almost all supporting evidence derives from the full-length parent protein rather than TB-500 itself — a distinction that will matter considerably during rulemaking.
06 Sep 2026
Research Pipeline
Retatrutide: Lilly's Triple-Agonist Peptide With Phase 3 Data in Hand, a Q1 2027 BLA Filing Planned, and a 28% Weight-Loss Benchmark to Defend
Eli Lilly confirmed on 23 July 2026 that it plans to submit a Biologics Licence Application for retatrutide in the first quarter of 2027, following completion of its TRIUMPH Phase 3 programme. With obesity trial data showing up to 28% mean body-weight loss at 80 weeks and TRIUMPH-3 cardiovascular outcomes data reported in July 2026, retatrutide is the furthest-advanced triple GIP/GLP-1/glucagon receptor agonist in the industry pipeline.
05 Sep 2026
Research Pipeline
Epitalon: The Pineal Tetrapeptide With a Favourable PCAC Vote, Telomere-Focused Preclinical Data, and No Approved Human Indication
On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend Epitalon for the 503A Bulks List — overriding FDA staff's written objection. The tetrapeptide's evidence base remains almost entirely preclinical and concentrated in a single research group, making the path from advisory vote to compounding approval, let alone clinical adoption, a lengthy one.
04 Sep 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide With a Divided Regulatory Status, Decades of Preclinical Evidence, and a PCAC Review Pending Before February 2027
GHK-Cu occupies an unusual position in the FDA compounding framework: its nominations were withdrawn in April 2026, prompting a brief removal from Category 1, only for one nominator to partially reverse course weeks later. The FDA has now scheduled a PCAC review before February 2027 for both its injectable and non-injectable forms. For UK research-procurement teams, the compound's five-decade preclinical record contrasts with a near-total absence of human efficacy trials.
03 Sep 2026